Abstract:Treating HIV is made difficult by the evolution of antimicrobial resistant mutants of that occurs in the life cycle of this virus. This has led to the evolution of numerous inhibition mechanism that intends to challenges the replication of this virus. One such approach is the application of molecular modelling in drug discovery. In this study the application of computer aided drug design were employed in finding an inhibitor that can contribute in finding a suitable drug candidate. Firstly, the ZINC database was screened using the Lipinski’s rule of five, and compounds having similar biological features were classified and grouped together into a compound library. Secondly, the co-crystallized structure of 1rv7 wild type of HIV-1 protease was used to construct a pharmacophore model that was used to screen further, the ZINC database Ligand stored in the compound library. Thestructure-basedpharmacophore was created by mimicking the three main active features of the co-crystallized structure from the Protein Data Bank, namely, 82 and 84, I50 and I150 residues.Thirdly, a total of twenty-six of the compounds that had less than 0,5 RMSD were identified and selected. Fourthly, based on the best docking ligands, ten of these compounds having high binding affinity were selected. These compounds are ZINC_001456687980 (-8.0), ZINC_001445792073 (-7.8) and ZINC_001461099137 (-7.4), successively. However, ZINC_001461099137 was eliminated based on unfavorable donor-donor interaction. The subsequent compound, ZINC_000015276352 was then placed on the top three leading compounds with a binding affinity of (-6.9). Fifthly, the ADMET property analysis was used on the top ten compounds, and the compounds that satisfied the analysis were, ZINC_001456687980, ZINC_000015276352, ZINC_001359888321 and ZINC_001460445290. The main properties that included the BBB permeation, the gastrointestinal absorption, pan assay interference structure (PAINS), were analyzed. ZINC_001456687980 had two violation (mw >350, XLOGP3>3.5),whiles ZINC_000015276352 had three violations (mw > 350, XLOGP3 > 3.5, rotatable > 7). Lastly, only two top compound underwent molecular dynamics simulations. Molecular dynamics simulation revealed the formation of numerous bond interactions between ZINC_001456687980 and ZINC_000015276352 together with the target protein.

Accessing anti-HIV activity through the attenuation of USP18 activity: novel insights from molecular dynamic simulations, free-energy profiling, and multi-cellular inhibition assays

USP49 Potently Stabilizes APOBEC3G Protein by Removing Ubiquitin and Inhibits HIV-1 Replication

Structure-based virtual screening, ADMET profiling, and molecular dynamics simulation studies on HIV-1 protease for identification of active phytocompounds as potential anti-HIV agents

Identification of ZINC inhibitors for HIV-1 Protease through Structure-Based Pharmacophore, Virtual Screening, ADMET and Molecular Dynamics Simulation

Rational Design of Sulfonyl-?-AApeptides as Highly Potent HIV-1 Fusion Inhibitors with Broad-Spectrum Activity

Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies

Molecular Docking and Molecular Dynamics Simulation to Predict Inhibitors Against HIV Envelope 1 Protein

Strategies for Inhibiting Function of HIV-1 Accessory Proteins: A Necessary Route to AIDS Therapy?

2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies

Identification of a Novel HIV‐1 Integrase Strand Transfer Inhibitor: A Synergistic Approach Combining Pharmacophore Modelling and In Vitro Assays

Design, Synthesis, and Biological Evaluation of Highly Potent Small Molecule–Peptide Conjugates As New HIV-1 Fusion Inhibitors

Evaluation of Novel HIV-1 Protease Inhibitors with DRV-resistance by Utilizing 3D-QSAR Molecular Docking and Molecular Dynamics Simulation

Ectopic USP15 expression inhibits HIV-1 transcription involving changes in YY1 deubiquitination and stability

Evaluating The Potency Of Hiv-1 Protease Drugs To Combat Resistance

Virtual Screening, Biological Evaluation, And 3d-Qsar Studies Of New Hiv-1 Entry Inhibitors That Function Via The Cd4 Primary Receptor

Quantum mechanical analysis of newly synthesized HIV-1 protease inhibitors: evaluation of wild-type and resistant strain binding interactions

Identifying the Molecular Mechanics and Binding Dynamics Characteristics of Potent Inhibitors to HIV‐1 Protease

Computational identification and analysis of CNP0269688 as a natural product inhibitor disrupting the interaction between the HIV matrix domain and tRNA

Why is Substrate Peptide Binding Unsusceptible to Multidrug-Resistant Mutations in HIV-1 Protease? A Structural and Energetic Analysis

Proposal of pharmacophore model for HIV reverse transcriptase inhibitors: Combined mutational effect analysis, molecular dynamics, molecular docking and pharmacophore modeling study

Prediction of the binding mode and resistance profile for a dual-target pyrrolyl diketo acid scaffold against HIV-1 integrase and reverse-transcriptase-associated ribonuclease H.